Taibang is a China-based biopharmaceutical company that develops and manufactures human plasma-based products for the treatment of hepatitis B, rabies, and tetanus diseases... Read more
Taibang is a China-based biopharmaceutical company that develops and manufactures human plasma-based products for the treatment of hepatitis B, rabies, and tetanus diseases... Read more
Chairman & CEO
Joseph Chow
News
Aug 12, 2022
BNN Bloomberg
Taibang: Centurium-Backed Taibang Picks CICC, JPMorgan for HK IPO, Sources Say - BNN Bloomberg
Aug 10, 2022
Global Legal Chronicle
Taibang: Taibang Biologic Group's $300 Million Equity Raising
Aug 03, 2022
Zawya
CBPO: China's Taibang Biologic raises $300mln, led by Abu Dhabi Investment Authority unit, GIC
Aug 02, 2022
Equal Ocean
CBPO: Blood Products Company Taibang Bags USD 300 Mn of Investment
Nov 17, 2021
PR Newswire
Press Release: CBPO : China Biologic Privatization Transaction Led by Centurium Capital Wins AVCJ "Deal of the Year - Large Cap"
May 10, 2021
Global Legal Chronicle
CBPO: China Biologic's $1.1 Billion Loan
Apr 22, 2021
DealStreetAsia
CBPO: Centurium-led consortium completes $4.76b take-private deal of China Biologic
Mar 30, 2021
MarketScreener
CBPO: China Biologic Products : CBPO 4Q20 Presentation Material
Mar 29, 2021
BioSpace
CBPO: China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
Mar 29, 2021
Markets Insider
CBPO: China Biologic Products Inc. Q4 adjusted earnings Beat Estimates
Taibang Biologic Group Competitors
1
2
3
4
5
6
7
8
9
10